BioCentury

8:00 AM GMT, Nov 16, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III EOS trial in 933 patients showed that once-daily 500 ug oral Daxas plus Serevent salmeterol for 24 weeks significantly improved mean pre- and post-bronchodilator FEV1 by 49 and 60 mL, respectively, vs. placebo plus

Read the full 428 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.